Three‐year outcomes of peripheral blood mononuclear cells vs purified CD34 (+) cells in the treatment of angiitis‐induced no‐option critical limb ischemia and a cost‐effectiveness assessment: A randomized single‐blinded noninferiority trial

For patients with angiitis‐induced critical limb ischemia (AICLI), cell transplantation, such as purified CD34(+) cells (PCCs) and peripheral blood mononuclear cells (PBMNCs), is gradually being used as a promising treatment. This was the first randomized single‐blinded noninferiority trial (number:...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Hao, Pan, Tianyue, Fang, Yuan, Fang, Gang, Liu, Yifan, Jiang, Xiaolang, Chen, Bin, Wei, Zheng, Gu, Shiyang, Liu, Peng, Fu, Weiguo, Dong, Zhihui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Human Clinical Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046046/
https://www.ncbi.nlm.nih.gov/pubmed/33399273
http://dx.doi.org/10.1002/sctm.20-0033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046046/
https://www.ncbi.nlm.nih.gov/pubmed/33399273
http://dx.doi.org/10.1002/sctm.20-0033

Ejemplares similares